B. A. Sachais, J. N. Logue, and M. S. Carey, Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis, Arch Neurol, vol.34, pp.422-430, 1977.

A. Mirijello, F. Caputo, G. Vassallo, B. Rolland, C. Tarli et al., GABAB agonists for the treatment of alcohol use disorder, Curr Pharm Des, vol.21, pp.3367-72, 2015.

A. K. Rose and A. Jones, Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis, Addiction, vol.113, pp.1396-406, 2018.

C. Palpacuer, R. Duprez, A. Huneau, C. Locher, R. Boussageon et al., Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network metaanalyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate, Addiction, vol.113, pp.220-257, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01696955

R. De-beaurepaire, Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients, Front Psychiatry, vol.3, p.103, 2012.

L. Rigal, C. Alexandre-dubroeucq, R. De-beaurepaire, L. Jeunne, C. Jaury et al., Abstinence and "low-risk" consumption 1 year after the initiation of high-dose baclofen: a retrospective study among "high-risk" drinkers, Alcohol Alcohol, vol.47, pp.439-481, 2012.

B. Rolland, R. Bordet, and O. Cottencin, Alcohol-dependence: the current French craze for baclofen, Addiction, vol.107, pp.848-857, 2012.

A. Pastor, D. Jones, and J. Currie, High-dose baclofen for treatmentresistant alcohol dependence, J Clin Psychopharmacol, vol.32, pp.266-274, 2012.

A. Thompson, L. Owens, P. Richardson, and M. Pirmohamed, Systematic review: baclofen dosing protocols for alcohol use disorders used in observational studies, Eur Neuropsychopharmacol, vol.27, pp.1077-89, 2017.

A. Ort, M. Kometer, J. Rohde, E. Seifritz, and F. X. Vollenweider, The role of GABAB receptors in human reinforcement learning, Eur Neuropsychopharmacol, vol.24, pp.1606-1620, 2014.

J. Chick and D. J. Nutt, Substitution therapy for alcoholism: time for a reappraisal?, J Psychopharmacol, vol.26, pp.205-217, 2012.

B. Rolland, R. Bordet, S. Deheul, and O. Cottencin, Baclofen for alcohol-dependence: anticraving or partial substitution?, J Clin Psychopharmacol, vol.33, pp.280-281, 2013.

M. Costa, B. Rolland, and P. Carrieri, The need for patient-tailored dosing of baclofen in future clinical trials, Eur Neuropsychopharmacol, vol.28, pp.656-663, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02090030

B. Pignon, J. Labreuche, M. Auffret, S. Gautier, S. Deheul et al., The dose-effect relationship of baclofen in alcohol dependence: a 1-year cohort study, Hum Psychopharmacol, vol.32, 2017.

E. M. Beraha, E. Salemink, A. E. Goudriaan, A. Bakker, D. De-jong et al., Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, doubleblind controlled trial, Eur Neuropsychopharmacol, vol.26, pp.1950-1959, 2016.

M. Reynaud, H. Aubin, F. Trinquet, B. Zakine, C. Dano et al., A randomized, placebo-controlled study of high-dose baclofen in alcoholdependent patients-the ALPADIR study, Alcohol Alcoholism, pp.1-8, 2017.

P. Jaury, High Dose Baclofen for the Treatment of Alcohol Drinkers (BACLOVILLE), ISBRA ESBRA World Congress on Alcohol an Alcoholism, 2016.

C. A. Müller, O. Geisel, P. Pelz, V. Higl, J. Krüger et al., High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial, Eur Neuropsychopharmacol, vol.25, pp.1167-77, 2015.

C. Chaignot, A. Weill, P. Ricordeau, and A. F. , Use in France of Baclofen for alcohol dependence from, cohort study based on the databases SNIIRAM and PMSI. Thérapie, vol.70, pp.443-53, 2007.

M. Auffret, J. Labreuche, A. Duhamel, S. Deheul, O. Cottencin et al., Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning offlabel prescribing practices: an example with baclofen and alcohol dependence in france, Drug Saf, vol.40, pp.257-62, 2017.

B. Rolland, J. Labreuche, A. Duhamel, S. Deheul, S. Gautier et al., Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation, Eur Neuropsychopharmacol, vol.25, pp.1631-1637, 2015.

B. Rolland, M. Auffret, and N. Franchitto, Safety reports on the offlabel use of baclofen for alcohol-dependence: recommendations to improve causality assessment, Expert Opin Drug Saf, vol.15, pp.1-5, 2016.

G. Chen and A. N. Van-den-pol, Presynaptic GABAB autoreceptor modulation of P/Q-type calcium channels and GABA release in rat suprachiasmatic nucleus neurons, J Neurosci, vol.18, pp.1913-1935, 1998.

J. Kardos, L. Elster, I. Damgaard, P. Krogsgaard-larsen, and A. Schousboe, Role of GABAB receptors in intracellular Ca2+ homeostasis and possible interaction between GABAA and GABAB receptors in regulation of transmitter release in cerebellar granule neurons, J Neurosci Res, vol.39, pp.646-55, 1994.

D. Boels, C. Victorri-vigneau, M. Grall-bronnec, A. Touré, A. Garnier et al., Baclofen and alcohol-dependent patients: a real risk of severe self-poisoning, Basic Clin Pharmacol Toxicol, vol.121, pp.353-362, 2017.

M. Léger, M. Brunet, L. Roux, G. Lerolle, N. Boels et al., Baclofen self-poisoning in the era of changing indication: multicentric reports to a french poison control centre, Alcohol Alcohol, vol.52, pp.665-70, 2017.

F. Pelissier, L. De-haro, F. Cardona, C. Picot, E. Puskarczyk et al., Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, Clin Toxicol, vol.55, pp.275-84, 2008.

N. Franchitto, B. Jullian, J. Salles, F. Pelissier, and R. B. , Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians, Exp Opin Drug Metabol Toxicol, vol.13, pp.669-77, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01906292

C. Haw and K. Hawton, Life problems and deliberate self-harm: Associations with gender, age, suicidal intent and psychiatric and personality disorder, J Affect Disord, vol.109, pp.139-187, 2008.

B. Rolland, T. Valin, C. Langlois, M. Auffret, S. Gautier et al., Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study, Int Clin Psychopharmacol, vol.30, pp.49-53, 2015.

M. Auffret, B. Rolland, S. Deheul, V. Loche, C. Hennaux et al., Severe tinnitus induced by off-label baclofen, Ann Pharmacother, vol.48, pp.656-665, 2014.

L. B. Kiel, L. Hoegberg, T. Jansen, J. A. Petersen, and K. P. Dalhoff, A nationwide register-based survey of baclofen toxicity, Basic Clin Pharmacol Toxicol, vol.116, pp.452-458, 2015.

B. Rolland, S. Deheul, T. Danel, R. Bordet, and O. Cottencin, A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol, Alcohol Alcohol, vol.47, pp.577-80, 2012.

J. M. Chawla and R. Sagar, Baclofen-induced psychosis, Ann Pharmacother, vol.40, pp.2071-2074, 2006.

P. A. Geoffroy, M. Auffret, S. Deheul, R. Bordet, O. Cottencin et al., Baclofen-induced manic symptoms: case report and systematic review, Psychosomatics, vol.55, pp.326-358, 2014.

A. Takahashi, R. X. Lee, T. Iwasato, S. Itohara, H. Arima et al., Glutamate input in the dorsal raphe nucleus as a determinant of escalated aggression in male mice, J Neurosci, vol.35, pp.6452-63, 2015.

J. Tanaka, N. Mashiko, A. Kawakami, A. Ushigome, and M. Nomura, GABAergic systems in the nucleus tractus solitarius regulate noradrenaline release in the subfornical organ area in the rat, Autonom Neurosci, vol.100, pp.58-65, 2002.

R. Tao, Z. Ma, and S. B. Auerbach, Differential regulation of 5-hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats, Br J Pharmacol, vol.119, pp.1375-84, 1996.

K. C. Morley, A. Baillie, S. Leung, G. Addolorato, L. Leggio et al., Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety, Alcohol Alcohol, vol.49, pp.654-60, 2014.

P. A. Geoffroy and B. Rolland, Does Baclofen have antidepressant qualities?, vol.42, pp.384-389, 2016.

H. Yu, S. G. Benitez, S. Jung, F. Altamirano, L. E. Kruse et al., GABAergic signaling in the rat pineal gland, J Pineal Res, vol.61, pp.69-81, 2016.

P. Mare? and R. ?lamberová, Opposite effects of a GABAB antagonist in two models of epileptic seizures in developing rats, Brain Res Bull, vol.71, pp.160-166, 2006.

P. F. Smith, Y. Zheng, and C. L. Darlington, Revisiting baclofen for the treatment of severe chronic tinnitus, Front Neurol, vol.3, p.34, 2012.

W. M. Connelly, S. J. Fyson, A. C. Errington, C. P. Mccafferty, D. W. Cope et al., GABAB receptors regulate extrasynaptic GABAA receptors, J Neurosci, vol.33, pp.3780-3785, 2013.

K. Gerrow and A. Triller, GABAA receptor subunit composition and competition at synapses are tuned by GABAB receptor activity, Mol Cell Neurosci, vol.60, pp.97-107, 2014.

P. Y. Olivier, M. Joyeux-faure, T. Gentina, S. H. Launois, M. P. Ortho et al., Severe central sleep apnea associated with chronic baclofen therapy, Chest, vol.149, pp.127-158, 2016.

O. Pierrefiche, A. S. Foutz, and M. Denavit-saubié, Effects of GABAB receptor agonists and antagonists on the bulbar respiratory network in cat, Brain Res, vol.605, pp.77-84, 1993.

B. Rolland, E. Jaillette, L. Carton, C. Bence, S. Deheul et al., Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder, J Clin Psychopharmacol, vol.34, pp.153-159, 2014.

R. De-beaurepaire, The use of very high-doses of baclofen for the treatment of alcohol-dependence: a case series, Front Psychiatry, vol.5, p.143, 2014.

L. Rigal, L. Hoang, L. , A. , C. Pinot et al., Tolerability of high-dose baclofen in the treatment of patients with alcohol disorders: a retrospective study, Alcohol Alcohol, vol.50, pp.551-558, 2015.

C. Bence, O. Cottencin, S. Deheul, S. Gautier, R. Bordet et al., Baclofeninduced edema in alcohol use disorders, J Clin Pharmacol, vol.54, pp.478-81, 2014.

N. Y. Leung, I. M. Whyte, and G. K. Isbister, Baclofen overdose: defining the spectrum of toxicity, Emerg Med Aust, vol.18, pp.77-82, 2006.

E. Pape, E. Roman, J. Scala-bertola, C. Thivilier, L. Javot et al., Death of an alcohol-dependent patient following intentional drug intoxication: implication of baclofen?, Eur Addict Res, vol.20, pp.300-304, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01471482

, Real-Life Baclofen in France Between, Agence Française de Sécurité du Médicaments et des produits de santé (ANSM), 2009.

C. Villier, E. Schir, and M. Mallaret, Adverse Effects of Baclofen in the Treatment of Addictions, National Pharmacovigilance Monitoring, 2011.

A. Braillon and F. Naudet, Baclofen and alcohol use disorders: from miracle to mirage, Eur Neuropsychopharmacol, vol.27, pp.691-693, 2017.
DOI : 10.1016/j.euroneuro.2017.05.003

M. Naassila and F. Paille, Société Française d'Alcoologie. Baclofen and Alcohol Use: What Can be Said in 2018, 2018.

M. Auffret, B. Rolland, A. Caous, L. Gaboriau, S. Deheul et al., On-the-ground application of the "temporary recommendation for use" regulatory measure on off-label use of baclofen for alcohol dependence in France: A regional survey of community pharmacies, Fundam Clin Pharmacol, vol.32, pp.234-242, 2017.